Episode notes
Authors: Redenti et al.
DOI: 10.1038/s41586-024-08033-4
Central Idea: This study engineers a probiotic E. coli Nissle 1917 strain to deliver tumor-specific neoantigens, creating a potent in situ cancer vaccine. This engineered probiotic effectively stimulates anti-tumor immunity and controls or eliminates tumor growth in mouse models of colorectal cancer and melanoma.
Key Concepts:
- Neoantigen-based vaccines: Neoantigens are tumor-specific mutations, making them ideal targets for immunotherapy. Existing neoantigen vaccine approaches have shown limited efficacy.
- Engineered E. coli vector: Researchers modified E. coli Nissle 1917 to enhance neoantigen production and delivery. Key modifi ...